The Dignity Health website is moving to CommonSpirit.org to deliver a more patient-centered digital experience across CA, AZ, and NV.
(YAVAPAI - Jan. 10, 2022) – In November 2020, the U.S. Food and Drug Administration issued an Emergency Use Authorization to allow the use of monoclonal antibodies (MAB) for the treatment of mild to moderate symptoms of COVID-19.
Two COVID monoclonal antibody products – Regeneron and BAM/Ete – are not effective against the Omicron variant of the COVID-19 virus. Dignity Health, Yavapai Regional Medical Center (YRMC) is no longer administering Regeneron and BAM/Ete treatments based on current recommendations due to the high proportion of Omicron cases present in Arizona.
YRMC will continue to offer Sotrovimab COVID monoclonal antibody treatments, which have shown to be effective against the Omicron variant.
The supply of Sotrovimab is severely depleted and will be administered to only the highest risk patients based on availability.
What are the criteria for COVID MAB therapy (Sotrovimab)?
Who cannot receive COVID MAB therapy (Sotrovimab)?
How do I schedule an appointment for COVID MAB therapy (Sotrovimab)?
###
Publish date:
Monday, January 10, 2022